Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (DE:07X)
BERLIN:07X
Annovis Bio (07X) Stock Price & Analysis
2 Followers
07X Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.42 - €18.10
Previous Close€8.89
Volume400.00
Average Volume (3M)926.00
Market Cap
€89.48M
Enterprise Value€83.61M
Total Cash (Recent Filing)$6.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta0.31
Next Earnings
Aug 05, 2024EPS Estimate
-€0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,171,480
10 Day Avg. Volume0
30 Day Avg. Volume926
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)14.03
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.25
Forecast
1Y Price Target
€19.29Price Target Upside116.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Annovis Bio News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyBuntanetap has shown promising signs of effectiveness in Alzheimer's disease trials, hinting at potential across neurodegenerative diseases and sparking optimism for forthcoming Parkinson's disease results.
Financial StabilityThe company boasts a solid cash runway, ensuring financial stability through key trial announcements, bolstering investor confidence.
Upcoming Data ReleaseAnnovis Bio is on the brink of releasing pivotal trial results for buntanetap in Parkinson’s disease, which may substantially boost the stock's value.
Bears Say
Clinical Trial SetbacksInvestors greeted the top-line Phase 2/3 results in AD with skepticism, indicating concerns over the drug's efficacy and future prospects.
Financial Health ConcernsAnnovis Bio reported financial results with a lower than expected cash position, indicating a possible need for additional funding.
Regulatory And Commercialization RisksRisks include negative clinical results and potential difficulties in commercialization and regulatory approval, presenting a worrisome outlook for the company's pipeline.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
19.60% Other Institutional Investors
80.40% Public Companies and
Individual Investors
07X FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was €4.42 and its highest was €18.10 in the past 12 months.
What is Annovis Bio’s market cap?
Currently, no data Available
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Aug 05, 2024 which is in 81 days.
How were Annovis Bio’s earnings last quarter?
Currently, no data Available
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -€0.52.
How many shares outstanding does Annovis Bio have?
Currently, no data Available
What happened to Annovis Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in DE:07X
---
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€19.29 (116.98% Upside)
€19.29 (116.98% Upside)
Blogger Sentiment
Bullish
DE:07X Sentiment 87%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.03%
12-Months-Change
Fundamentals
Return on Equity
-566.49%
Trailing 12-Months
Asset Growth
-69.42%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio Inc is a United States based clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
---
07X Stock 12 Month Forecast
Average Price Target
€19.29
▲(116.98% Upside)
Technical Analysis
Best Analysts Covering 07X
1 Year
1 Year Success Rate
3/15 ratings generated profit
1 Year Average Return
-19.68%
reiterated a buy rating 4 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -19.68% per trade.
---